![Thomas Guiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 9 306 $ am 31.07.2026
Thomas G.
Guiel worked as Principal at Invitrogen Corp., Vice President-Operations at CapForce, Inc., Chief Operating Officer & Executive Vice President at OncoPlex Diagnostics, Inc. from 2013 to 2018, and Chief Operating Officer at Oxford BioDynamics Plc.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OXFORD BIODYNAMICS PLC 0,15 % | 10.11.2025 | 6 288 146 ( 0,15 % ) | 9 306 $ | 31.07.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
OncoPlex Diagnostics, Inc.
 OncoPlex Diagnostics, Inc. Medical/Nursing ServicesHealth Services Operates a cancer diagnostics laboratory | Geschäftsführer | 01.01.2018 |
| OXFORD BIODYNAMICS PLC | Geschäftsführer | - |
| CAPFORCE INC. | Geschäftsführer | - |
Invitrogen Corp.
 Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and sells life science research kits and provides research services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
Invitrogen Corp.
Invitrogen Corp. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and sells life science research kits and provides research services | Electronic Technology |
OpGen, Inc.
 OpGen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technologies against life-threatening, antibiotic-resistant infections using molecular diagnostics and bioinformatics | Commercial Services |
OncoPlex Diagnostics, Inc.
OncoPlex Diagnostics, Inc. Medical/Nursing ServicesHealth Services Operates a cancer diagnostics laboratory | Health Services |
Oxford BioDynamics Plc
 Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
